Product logins

Find logins to all Clarivate products below.


Ruth Howells

Senior Director, Health Technology Assessment

Ruth is Head of Health Technology Assessment (HTA) at Clarivate. Ruth has overall responsibility for our Global HTA services and has been extensively involved in the development and strategic direction of HTAs, contributing in-depth knowledge of procedural processes. ​

Ruth oversees our global HTA services from early scientific advice, through local submissions and global HTA programs to post-submission support. With extensive experience of managing HTA submissions globally, Ruth works closely with our clients and in-house team, advising manufacturers on their role and requirements, and significantly contributes to the development and communication of the HTA strategy and evidence generation planning from an early stage.

Prior to joining Clarivate, Ruth worked for the National Institute for Health and Care Excellence (NICE) and has over 20 years’ experience in health outcomes research. Ruth has an MSc in Health Economics from the University of York and her experience in health outcomes research covers a wide range of therapeutic areas including, oncology (cervical cancer, head and neck cancer, colorectal cancer, breast cancer), respiratory disease, cardiology, nephrology, gynecology, gastroenterology and dermatology. Ruth is an expert in HTA for rare diseases and in innovative therapies such as cell and gene therapies.


arrow_forward
Get in touch with Ruth

Latest news

Partner news August 17, 2026
ShanghaiRanking’s Academic Ranking of World Universities 2026 Press Release

The 2026 Academic Ranking of World Universities (ARWU) is released today by ShanghaiRanking Consultancy. Since 2003, ARWU has been presenting the world’s top universities annually based on transparent methodology and…

Partner news
News August 13, 2026
Clarivate and KYBORA Partner to Help Biopharma Companies Execute Strategic Transaction Outcomes

This collaboration combines the scientific and commercial expertise of Clarivate’s Life Sciences & Healthcare Consulting practice with KYBORA’s global transaction execution capabilities to accelerate life sciences transactions London, U.K., August…

News August 12, 2026
Clarivate Enhances SkyRiver to Help Libraries Share, Reuse and Create Trusted Metadata

Combining community metadata sharing, institutional choice and AI-powered record creation LONDON, UK, August 12, 2026 – Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, today announced the…

Related resources

Bringing oncology medicines to patients faster: How Clarivate R&D Consulting supports every step to approval Bringing oncology medicines to patients faster: How Clarivate R&D Consulting supports every step to approval
Blog June 24, 2026
Bringing oncology medicines to patients faster: How Clarivate R&D Consulting supports every step to approval
ADC Biopharma Biotech Bispecific antibodies BsAb Clinical trials Development Oncology Pharma R&D Regulatory Research
Using AI-powered translational safety intelligence to anticipate drug safety issues earlier Using AI-powered translational safety intelligence to anticipate drug safety issues earlier
Blog June 22, 2026
Using AI-powered translational safety intelligence to anticipate drug safety issues earlier
Biopharma Biotech Clinical trials CMC Development R&D Real-World Data Regulatory Research Safety
Three uncomfortable truths about cell and gene therapy in regulatory affairs Three uncomfortable truths about cell and gene therapy in regulatory affairs
Blog May 28, 2026
Three uncomfortable truths about cell and gene therapy in regulatory affairs
Consulting Resource Center Regulatory
How the Inflation Reduction Act could impact access to more convenient therapeutics How the Inflation Reduction Act could impact access to more convenient therapeutics
Blog February 17, 2026
How the Inflation Reduction Act could impact access to more convenient therapeutics
Biopharma Biotech Commercialization Consulting Resource Center FDA HMO Insurance Launch Managed care Market Access North America Payer Pharma pricing Route of administration U.S.